Baquero F, Canedo E, RODRIGUEZ A, Jaso E
Arch Dis Child. 1975 May;50(5):367-72. doi: 10.1136/adc.50.5.367.
Forty-two infants, some premature, with enteropathogenic Esch. coli (EPEC) gastroenteritis were treated with an oral suspension of fosfomycin in a dose of 100 and 200 mg/kg per day. After the treatment there were 11 secondary clinical infections (6 reinfections and 5 relapses) which received a second treatment with fosfomycin. In total, 53 treatments were made with fosfomycin and in 92% of the cases there was both clinical and bacteriological cure. 93% of the EPEC strains were sensitive to fosfomycin in vitro, their minimum inhibitory concentrations being less than 64 mug/ml. The concentration of fosfomycin in blood and faeces was assayed by a diffusion plate microbiological method in a group of these children, showing that this antibiotic is partly absorbed and the rest eliminated in the faeces, where its concentration was found to be very high. Tolerance of the product was good, and there were neither toxic nor side effects.
42名患有致病性大肠杆菌(EPEC)肠胃炎的婴儿,其中一些为早产儿,接受了每日剂量为100和200毫克/千克的磷霉素口服混悬液治疗。治疗后出现了11例继发性临床感染(6例再感染和5例复发),这些患儿接受了磷霉素的二次治疗。总共用磷霉素进行了53次治疗,92%的病例实现了临床和细菌学治愈。93%的EPEC菌株在体外对磷霉素敏感,其最低抑菌浓度小于64微克/毫升。通过扩散平板微生物学方法对一组此类儿童的血液和粪便中的磷霉素浓度进行了测定,结果表明这种抗生素部分被吸收,其余部分在粪便中排出,在粪便中发现其浓度非常高。该产品耐受性良好,没有毒性和副作用。